Abbott Laboratories
Abbott Laboratories (ABL.DE) Stock Competitors & Peer Comparison
See (ABL.DE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ABL.DE | €74.26 | -1.54% | 129.8B | 24.44 | €3.05 | +2.79% |
| SYK.DE | €253.65 | +2.07% | 96.6B | 35.20 | €7.17 | +1.16% |
| 2M6.DE | €66.48 | -1.89% | 85.5B | 21.75 | €3.06 | +3.64% |
| BSX.F | €48.00 | -2.00% | 71.3B | 23.53 | €2.04 | N/A |
| SHL.DE | €35.70 | +2.38% | 39.3B | 18.62 | €1.89 | +2.84% |
| PHI1.DE | €23.00 | +1.63% | 21.5B | 24.34 | €0.93 | +3.75% |
| DRW3.DE | €88.80 | +0.11% | 1.6B | 11.71 | €7.42 | +2.34% |
| DRW8.DE | €71.20 | +2.59% | 1.3B | 9.35 | €7.42 | +2.34% |
| EUZ.DE | €15.55 | +3.53% | 953.6M | 19.54 | €0.78 | +1.09% |
| 6L9.F | €0.03 | +2400.00% | 207.2M | -0.05 | -€0.55 | N/A |
Stock Comparison
ABL.DE vs SYK.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, SYK.DE has a market cap of 96.6B. Regarding current trading prices, ABL.DE is priced at €74.26, while SYK.DE trades at €253.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas SYK.DE's P/E ratio is 35.20. In terms of profitability, ABL.DE's ROE is +0.12%, compared to SYK.DE's ROE of +0.15%. Regarding short-term risk, ABL.DE is less volatile compared to SYK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check SYK.DE's competition here
ABL.DE vs 2M6.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, 2M6.DE has a market cap of 85.5B. Regarding current trading prices, ABL.DE is priced at €74.26, while 2M6.DE trades at €66.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas 2M6.DE's P/E ratio is 21.75. In terms of profitability, ABL.DE's ROE is +0.12%, compared to 2M6.DE's ROE of +0.10%. Regarding short-term risk, ABL.DE is less volatile compared to 2M6.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check 2M6.DE's competition here
ABL.DE vs BSX.F Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, BSX.F has a market cap of 71.3B. Regarding current trading prices, ABL.DE is priced at €74.26, while BSX.F trades at €48.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas BSX.F's P/E ratio is 23.53. In terms of profitability, ABL.DE's ROE is +0.12%, compared to BSX.F's ROE of +0.15%. Regarding short-term risk, ABL.DE is more volatile compared to BSX.F. This indicates potentially higher risk in terms of short-term price fluctuations for ABL.DE.Check BSX.F's competition here
ABL.DE vs SHL.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, SHL.DE has a market cap of 39.3B. Regarding current trading prices, ABL.DE is priced at €74.26, while SHL.DE trades at €35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas SHL.DE's P/E ratio is 18.62. In terms of profitability, ABL.DE's ROE is +0.12%, compared to SHL.DE's ROE of +0.12%. Regarding short-term risk, ABL.DE is less volatile compared to SHL.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check SHL.DE's competition here
ABL.DE vs PHI1.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, PHI1.DE has a market cap of 21.5B. Regarding current trading prices, ABL.DE is priced at €74.26, while PHI1.DE trades at €23.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas PHI1.DE's P/E ratio is 24.34. In terms of profitability, ABL.DE's ROE is +0.12%, compared to PHI1.DE's ROE of +0.08%. Regarding short-term risk, ABL.DE is less volatile compared to PHI1.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check PHI1.DE's competition here
ABL.DE vs DRW3.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, DRW3.DE has a market cap of 1.6B. Regarding current trading prices, ABL.DE is priced at €74.26, while DRW3.DE trades at €88.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas DRW3.DE's P/E ratio is 11.71. In terms of profitability, ABL.DE's ROE is +0.12%, compared to DRW3.DE's ROE of +0.10%. Regarding short-term risk, ABL.DE is less volatile compared to DRW3.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check DRW3.DE's competition here
ABL.DE vs DRW8.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, DRW8.DE has a market cap of 1.3B. Regarding current trading prices, ABL.DE is priced at €74.26, while DRW8.DE trades at €71.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas DRW8.DE's P/E ratio is 9.35. In terms of profitability, ABL.DE's ROE is +0.12%, compared to DRW8.DE's ROE of +0.10%. Regarding short-term risk, ABL.DE is less volatile compared to DRW8.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check DRW8.DE's competition here
ABL.DE vs EUZ.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, EUZ.DE has a market cap of 953.6M. Regarding current trading prices, ABL.DE is priced at €74.26, while EUZ.DE trades at €15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas EUZ.DE's P/E ratio is 19.54. In terms of profitability, ABL.DE's ROE is +0.12%, compared to EUZ.DE's ROE of +0.21%. Regarding short-term risk, ABL.DE is less volatile compared to EUZ.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check EUZ.DE's competition here
ABL.DE vs 6L9.F Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, 6L9.F has a market cap of 207.2M. Regarding current trading prices, ABL.DE is priced at €74.26, while 6L9.F trades at €0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas 6L9.F's P/E ratio is -0.05. In terms of profitability, ABL.DE's ROE is +0.12%, compared to 6L9.F's ROE of -0.85%. Regarding short-term risk, ABL.DE is less volatile compared to 6L9.F. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check 6L9.F's competition here
ABL.DE vs SBS.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, SBS.DE has a market cap of 203.7M. Regarding current trading prices, ABL.DE is priced at €74.26, while SBS.DE trades at €17.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas SBS.DE's P/E ratio is -838.00. In terms of profitability, ABL.DE's ROE is +0.12%, compared to SBS.DE's ROE of -0.00%. Regarding short-term risk, ABL.DE is less volatile compared to SBS.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check SBS.DE's competition here
ABL.DE vs 6H90.SG Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, 6H90.SG has a market cap of 178.2M. Regarding current trading prices, ABL.DE is priced at €74.26, while 6H90.SG trades at €0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas 6H90.SG's P/E ratio is N/A. In terms of profitability, ABL.DE's ROE is +0.12%, compared to 6H90.SG's ROE of -0.40%. Regarding short-term risk, ABL.DE is less volatile compared to 6H90.SG. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check 6H90.SG's competition here
ABL.DE vs AAQ1.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, AAQ1.DE has a market cap of 30.9M. Regarding current trading prices, ABL.DE is priced at €74.26, while AAQ1.DE trades at €2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas AAQ1.DE's P/E ratio is -6.36. In terms of profitability, ABL.DE's ROE is +0.12%, compared to AAQ1.DE's ROE of -0.24%. Regarding short-term risk, ABL.DE is less volatile compared to AAQ1.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check AAQ1.DE's competition here
ABL.DE vs GME.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, GME.DE has a market cap of 14.7M. Regarding current trading prices, ABL.DE is priced at €74.26, while GME.DE trades at €2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas GME.DE's P/E ratio is 7.74. In terms of profitability, ABL.DE's ROE is +0.12%, compared to GME.DE's ROE of +0.04%. Regarding short-term risk, ABL.DE is less volatile compared to GME.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check GME.DE's competition here
ABL.DE vs E8X.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, E8X.DE has a market cap of 1.5M. Regarding current trading prices, ABL.DE is priced at €74.26, while E8X.DE trades at €0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas E8X.DE's P/E ratio is -1.08. In terms of profitability, ABL.DE's ROE is +0.12%, compared to E8X.DE's ROE of +0.29%. Regarding short-term risk, ABL.DE is less volatile compared to E8X.DE. This indicates potentially lower risk in terms of short-term price fluctuations for ABL.DE.Check E8X.DE's competition here
ABL.DE vs CURK.DE Comparison May 2026
ABL.DE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ABL.DE stands at 129.8B. In comparison, CURK.DE has a market cap of 1.2M. Regarding current trading prices, ABL.DE is priced at €74.26, while CURK.DE trades at €0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ABL.DE currently has a P/E ratio of 24.44, whereas CURK.DE's P/E ratio is -0.25. In terms of profitability, ABL.DE's ROE is +0.12%, compared to CURK.DE's ROE of -0.68%. Regarding short-term risk, ABL.DE is more volatile compared to CURK.DE. This indicates potentially higher risk in terms of short-term price fluctuations for ABL.DE.Check CURK.DE's competition here